SCHEMBL19359347

SCHEMBL19359347

CC(C)CN1C(=O)CCC(N2C(=O)c3cccc(N)c3C2=O)C1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 12/20 0.54
CRBN Q96SW2 12/20 0.54
TNF P01375 1/20 0.54
IL1B P01584 1/20 0.54
TBXA2R P21731 1/20 0.54
IKZF1 Q13422 1/20 0.54
IKZF3 Q9UKT9 1/20 0.54
TMEM97 Q5BJF2 3/20 0.45
HTR2B P41595 2/20 0.45
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
HTR2A P28223 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
PABPC1 P11940 3/20 0.41
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25834486 0.90 DDB1 (0.53) DDB1CRBNTNFIL1BTBXA2R
SCHEMBL21571456 0.89 DDB1 (0.50) DDB1CRBNTNFIL1BTBXA2R
SCHEMBL21402717 0.89 DDB1 (0.50) DDB1CRBNTNFIL1BTBXA2R
SCHEMBL21571457 0.89 DDB1 (0.50) DDB1CRBNTNFIL1BTBXA2R
SCHEMBL19359168 0.88 DDB1 (0.56) DDB1CRBNTNFIL1BTBXA2R
SCHEMBL12041901 0.86 DDB1 (0.54) DDB1CRBNTNFIL1BTBXA2R
SCHEMBL21402672 0.85 DDB1 (0.48) DDB1CRBNTNFIL1BTBXA2R
SCHEMBL22313070 0.84 DDB1 (0.45) DDB1CRBNTNFIL1BTBXA2R
SCHEMBL4934289 0.84 DDB1 (0.54) DDB1CRBNTNFIL1BTBXA2R
SCHEMBL19359463 0.84 DDB1 (0.58) DDB1CRBNMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12564583-B2 Small molecules against cereblon to enhance effector T cell function Lee Moffitt Cancer Center and Research Institute, Inc. (US) 2026-03-03 US disclosed
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-20 US disclosed
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-20 US disclosed
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-20 US disclosed
CN-109153644-B Small molecules against CEREBLON to enhance effector T cell function H·李·莫菲特癌症中心研究有限公司 2022-10-21 CN disclosed
US-11395820-B2 Small molecules against cereblon to enhance effector t cell function H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-07-26 US disclosed
US-11395820-B2 Small molecules against cereblon to enhance effector t cell function H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-07-26 US disclosed
US-20210177825-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2021-06-17 US disclosed
US-20210177825-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2021-06-17 US disclosed
EP-3429996-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) 2019-01-23 EP disclosed
CN-109153644-A SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H·李·莫菲特癌症中心研究有限公司 2019-01-04 CN disclosed
WO-2017161119-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) 2017-09-21 WO disclosed
WO-2017161119-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) 2017-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12564583-B2 Small molecules against cereblon to enhance effector T cell function CRBN, CD4, ICOS DDB1 2979/4885CRBN 1/4885TNF 4523/4885
US-11395820-B2 Small molecules against cereblon to enhance effector t cell function CD4, GZMB, CRBN DDB1 2798/4885CRBN 3/4885TNF 3930/4885
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION CD4, CRBN, GZMB DDB1 3336/4885CRBN 2/4885TNF 3845/4885
US-20210177825-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION CD4, GZMB, CRBN DDB1 2798/4885CRBN 3/4885TNF 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.